| pubmed-article:9576202 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9576202 | lifeskim:mentions | umls-concept:C0024305 | lld:lifeskim |
| pubmed-article:9576202 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:9576202 | lifeskim:mentions | umls-concept:C0045093 | lld:lifeskim |
| pubmed-article:9576202 | lifeskim:mentions | umls-concept:C0205269 | lld:lifeskim |
| pubmed-article:9576202 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:9576202 | pubmed:dateCreated | 1998-5-26 | lld:pubmed |
| pubmed-article:9576202 | pubmed:abstractText | Three patients (aged 68-75 years) with histologically confirmed relapsed or refractory high-grade non-Hodgkin's lymphoma were entered in this pilot study in which gemcitabine 800 mg/m2 was given as a 30 min i.v. infusion once a week for 3 weeks. One patient responded with complete remission and the other two with partial remission and stable disease for 2 and 3 months, respectively. Haematological toxicity was modest with grade 4 leucopenia (one cycle) and grade 4 thrombocytopenia (two cycles). The activity and mild toxicity seen with gemcitabine suggest that this agent should be further evaluated in the treatment of high-grade non-Hodgkin's lymphoma. | lld:pubmed |
| pubmed-article:9576202 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9576202 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9576202 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9576202 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9576202 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9576202 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9576202 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9576202 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:9576202 | pubmed:issn | 0007-1048 | lld:pubmed |
| pubmed-article:9576202 | pubmed:author | pubmed-author:OhiHH | lld:pubmed |
| pubmed-article:9576202 | pubmed:author | pubmed-author:BernellPP | lld:pubmed |
| pubmed-article:9576202 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9576202 | pubmed:volume | 101 | lld:pubmed |
| pubmed-article:9576202 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9576202 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9576202 | pubmed:pagination | 203-4 | lld:pubmed |
| pubmed-article:9576202 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:9576202 | pubmed:meshHeading | pubmed-meshheading:9576202-... | lld:pubmed |
| pubmed-article:9576202 | pubmed:meshHeading | pubmed-meshheading:9576202-... | lld:pubmed |
| pubmed-article:9576202 | pubmed:meshHeading | pubmed-meshheading:9576202-... | lld:pubmed |
| pubmed-article:9576202 | pubmed:meshHeading | pubmed-meshheading:9576202-... | lld:pubmed |
| pubmed-article:9576202 | pubmed:meshHeading | pubmed-meshheading:9576202-... | lld:pubmed |
| pubmed-article:9576202 | pubmed:meshHeading | pubmed-meshheading:9576202-... | lld:pubmed |
| pubmed-article:9576202 | pubmed:meshHeading | pubmed-meshheading:9576202-... | lld:pubmed |
| pubmed-article:9576202 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9576202 | pubmed:articleTitle | Promising activity of gemcitabine in refractory high-grade non-Hodgkin's lymphoma. | lld:pubmed |
| pubmed-article:9576202 | pubmed:affiliation | Department of Medicine, Karolinska Institute at Danderyd Hospital, Stockholm, Sweden. | lld:pubmed |
| pubmed-article:9576202 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9576202 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9576202 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9576202 | lld:pubmed |
